KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.

Patrick Hanafin, Yu Liu Ho, Theodoros Papathanasiou, Giulia Fulci, Neal Sule, Brandon E Kremer, Geraldine Ferron-Brady

Target Oncol 20(5) 833-845

PMID40958065
PMCIDPMC12454471
DOI10.1007/s11523-025-01174-0
发表日期2025-09-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In the phase 3 DREAMM-8 study (NCT04484623), belantamab mafodotin (anti-B-cell maturation antigen [BCMA] antibody-drug conjugate with a monomethyl auristatin F payload) with pomalidomide and dexamethasone (BPd) showed significant progression-free survival benefit in second-line or later relapsed/refractory multiple myeloma (RRMM). OBJECTIVE: This exposure-response analysis explored the relationship between belantamab mafodotin cycle 1 exposure and efficacy/safety and predicted the benefit-risk profile of belantamab mafodotin at an initial dose of 1.9 versus 2.5 mg/kg using DREAMM-8 data. PATIENTS AND METHODS: In the BPd arm of DREAMM-8, belantamab mafodotin was dosed at 2.5 mg/kg intravenously in cycle 1, then at 1.9 mg/kg every 4 weeks from cycle 2 onward. Cycle 1 belantamab mafodotin and free payload exposures derived from population pharmacokinetic analysis were used to perform exposure-efficacy/exposure-safety analyses for probability of/time to first event. Selected covariate effects were evaluated. RESULTS: Higher belantamab mafodotin cycle 1 exposure was associated with deeper response (higher probabilities of complete response or better [≥ CR] and minimal residual disease negativity), but not with grade ≥ 3 ocular adverse events (oAEs)/ophthalmic exam findings. Benefit-risk assessment showed that an initial belantamab mafodotin dose of 1.9 mg/kg instead of 2.5 mg/kg would result in reduction in probability of ≥ CR without reduction in oAEs/ophthalmic exam findings. CONCLUSIONS: An initial belantamab mafodotin dose of 2.5 mg/kg for BPd yields deeper responses versus 1.9 mg/kg with minimal change in safety outcomes in RRMM. DREAMM-8 (NCT04484623) was registered at clinicaltrials.gov (21 July 2020).

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 1

Fig. 1 Progression-free survival stratified by cycle 1 belantamab mafodotin C avg quartile ( a ) and baseline sBCMA quartile ( b ). Duration of response stratified by cycle 1 belantamab mafodotin C avg quartile ( c ) and baseline sBCMA quartile ( d ). Quartiles are reported as median (minimum, maximum). ADC antibody-drug conjugate, sBCMA soluble B-cell maturation antigen, C avg average concentration over the dosing interval, Q quartile

A

Progression-free survival

Fig. 1 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival

Fig. 1 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Duration of response

Fig. 1 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Duration of response

Fig. 1 · Panel D

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Fig. 2 Relationship between probabilities of clinical response and cycle 1 belantamab mafodotin C avg . The independent variable was divided into quartiles. Quartiles are reported as median (minimum, maximum). Points and error bars represent the observed proportions and 95% confidence intervals for each quartile (plotted at the median exposure within each quartile), respectively. The curves represent the prediction of the univariate logistic regression model, and the shaded region represents the 95% confidence interval of the prediction. The displayed p -value is for the logistic regression slope. ADC, antibody-drug conjugate; C avg , average concentration over the dosing interval; ≥ CR, complete response or better; MRD, minimal residual disease; ≥ OR, overall response or better; Q, quartile; ≥ VGPR, very good partial response or better
非 KM Figure
Fig. 3.Fig. 3. Time to response stratified by cycle 1 belantamab mafodotin C avg quartile. Quartiles are reported as median (minimum, maximum). ADC antibody-drug conjugate, C avg average concentration over the dosing interval, Q quartile
非 KM Figure
Fig. 4.Fig. 4. Relationship between probability of ≥ VGPR, oAEs, OEFs, and cycle 1 belantamab mafodotin C avg . The independent variable was divided into quartiles. Quartiles are reported as median (minimum, maximum). Points and error bars represent the observed proportions and 95% confidence intervals for each quartile (plotted at the median exposure within each quartile), respectively. The curves represent the prediction of the univariate logistic regression model, and the shaded region represents the 95% confidence interval of the prediction. The displayed p -value is for the logistic regression slope. ADC antibody-drug conjugate, BCVA best corrected visual acuity, C avg average concentration over the dosing interval, KVA keratopathy and visual acuity, oAE ocular adverse event, OEF ophthalmic exam finding, Q quartile; ≥ VGPR very good partial response or better
非 KM Figure